FOLH1 and neuroendocrine neoplasm: The current standard treatment scheme for [177Lu]Lu-PSMA RLT is based on previous experiences with peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET) consisting of four cycles of 7.4 GBq [177Lu]Lu-DOTA-TATE per cycle [18].